CLS-logo.png Myeloid cells are an important potential target immune cell for immunotherapy cancer treatment. Screening molecules or biologics for their ability to drive phenotypic and functional immune cell changes in the tumour microenvironment (TME) could be key to your immuno-oncology discovery program.

Our services

We provide custom assays to investigate the effect of client compounds on a variety of myeloid cells. Whatever your myeloid cell of interest (monocyte, macrophage, dendritic cell (DC) or granulocyte), we can tailor our myeloid cell assays to meet your needs. We offer both monoculture assays, to examine the effect of your compound on a single cell type, as well as mixed cell assays.

Whatever your scientific question, our immunology expertise and myeloid cell experience can support you in your IO discovery programs. Our suite of myeloid cell assays includes:

  • M1 and M2 macrophage differentiation assay
  • M1 and M2 macrophage polarisation assay
  • DC activation and maturation
  • Mixed lymphocyte reaction (MLR)
  • Allogeneic
  • Autologous
  • Antigen-specific T cell responses
  • Phagocytosis assays
  • M1-mediated T cell activation assay
  • M2 suppression assay
  • MDSC suppression assay


We can advise on the most suitable assay set up to understand your drug candidate mechanism of action (MOA), and tailor the assay accordingly. We offer both custom and standard assay readouts such as cytokine expression (ELISA, multiplex or MSD), proliferation, cell activation and cell surface markers (flow cytometry).

Find out more about our Suppression Assays.

Contact us today to learn more about our myeloid assays.

Expert solutions in myeloid cell assays. Contact us to discuss your challenges.
Contact sales Register now